



# IN THE UNITED STATES PATENT AND TRADEMARK OFFICE RECEIVED

OCT 2 8 2002

Applicants:

Collins, D.A. et al.

TECH CENTER 1600/290

Serial No.:

10/027,593

Group Art Unit: 1614

Filed:

October 25, 2001

Examiner: Not Yet Assigned

P#7

For:

Transcobalamin Binding Conjugates Useful for Treating Abnormal Cellular

Proliferation

Assistant Commissioner for Patents Washington, DC 20231

October 18, 2002

#### TRANSMITTAL OF INFORMATION DISCLOSURE STATEMENT

Sir:

Pursuant to the duty of disclosure under 37 CFR §§ 1.56, 1.97 and 1.98, Applicants cite the publication listed on the accompanying Form PTO-1449A. A copy of the reference is enclosed as well as a copy of the PCT Search Report. The citation of this information does not constitute an admission of priority or that any cited item is available as a reference, or a waiver of any right the applicant may have under the applicable statutes, Rules of Practice in patent cases, or otherwise.

If the Examiner determines a fee is required, the Commissioner is authorized to charge any requisite fees associated with this paper to Deposit Account No. 11-0980.

Respectfully submitted,

Hoang M. Vo

Registration No. 47,158

KING & SPALDING 191 Peachtree Street Atlanta, GA 30303 404-572-4600 (Telephone)

BEST AVAILAGE



## RECEIVED

OCT 2 & 2002

### **CERTIFICATE OF MAILING (37 CFR 1.8a)**

**TECH CENTER 1600/2900** 

I hereby certify that this Information Disclosure Statement, along with any paper referred to as being attached or enclosed, is being deposited with the United States Postal Service on the date shown below with sufficient postage as first-class mail in an envelope addressed to the Assistant Commissioner for Patents, Washington, D.C. 20231.

Hoang M.

Date: October 18, 2002

Substit	tute for form 1449A/PTO	5/		Complete if Known				0
	FORMATION I	102 <sup>23</sup>		Application Number	10/027,593			8
INI	FORMATION I	DIŞÇL	OSURE	Filing Date	October 25, 2001	<b>H</b>	00	00
STA	ATEMENT BY	APPL	ICANT	First Named Inventor.	Collins, D.A. et al.		8	- <del>-</del>
	(use as many sheets			Group Art Unit	N/A	W	~	111
	(use us many sneets	us necessi		Examiner Name	N/A		101	五
Sheet	1	of	1	Attorney Docket Number	COP 1008 US	8		天
		.,						Ш

	U.S. PATENT DOCUMENTS							
Examiner Initials *	Cite No. 1	1	ment d Code <sup>2</sup> f known)	Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear		

FOREIGN PATENT DOCUMENTS -								
Examiner Initials *	Cite No. <sup>1</sup>	For Office 3	reign Patent Doo Number	Kind Code <sup>2</sup> (if known)	Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document DD-MM-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	Té
		WO	96/04016		Amgen Inc.	15-02-1996		
		WO	94/27641		BioTech Australia	08-12-1994		
		WO	00/45857		Schering	10-08-2000		
	-	WO	02/42318		Collins	30 May 2002		
		WO	01/92288		Collins	06-12-2001		

OTHER PRIOR ART – NON PATENT LITERATURE DOCUMENTS						
Examiner Initials *	Cite No. 1	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T6			

# BEST AVAILABLE COPY

Examiner Signature	Date Considered	

<sup>\*</sup>EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Unique citation designation number. 2 See attached Kinds of U.S. Patent Documents. 3 Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). 4 For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. 5 Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. 6 Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U. S. Patent and Tradenark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.